TCR2 THERAPEUTICS INC's ticker is TCRR and the CUSIP is 87808K106. A total of 121 filers reported holding TCR2 THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 1.04 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $57,000 | +7.5% | 19,706 | +3.8% | 0.00% | – |
| Q1 2022 | $53,000 | -38.4% | 18,982 | +2.5% | 0.00% | – |
| Q4 2021 | $86,000 | -75.1% | 18,521 | -54.5% | 0.00% | – |
| Q3 2021 | $346,000 | +7.5% | 40,711 | +107.6% | 0.00% | – |
| Q2 2021 | $322,000 | -86.0% | 19,610 | -81.1% | 0.00% | -100.0% |
| Q1 2021 | $2,297,000 | -28.4% | 104,004 | +0.3% | 0.00% | -50.0% |
| Q4 2020 | $3,208,000 | -11.6% | 103,709 | -42.0% | 0.00% | 0.0% |
| Q3 2020 | $3,631,000 | +2900.8% | 178,721 | +2162.9% | 0.00% | – |
| Q2 2020 | $121,000 | +332.1% | 7,898 | +115.3% | 0.00% | – |
| Q1 2020 | $28,000 | -49.1% | 3,668 | -6.0% | 0.00% | – |
| Q4 2019 | $55,000 | +19.6% | 3,902 | +25.8% | 0.00% | – |
| Q3 2019 | $46,000 | +155.6% | 3,101 | +131.4% | 0.00% | – |
| Q2 2019 | $18,000 | – | 1,340 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| MPM BioImpact LLC | 6,741,964 | $208,528,000 | 18.01% |
| MPM ASSET MANAGEMENT LLC | 4,050,865 | $125,293,000 | 17.73% |
| Consonance Capital Management LP | 584,885 | $71,268,000 | 6.66% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 136,000 | $4,206,000 | 2.44% |
| Redmile Group, LLC | 2,832,888 | $87,621,000 | 1.06% |
| Altium Capital Management LP | 73,991 | $2,289,000 | 0.86% |
| PFM Health Sciences, LP | 775,794 | $23,995,000 | 0.84% |
| Soleus Capital Management, L.P. | 199,867 | $6,182,000 | 0.82% |
| MOODY ALDRICH PARTNERS LLC | 123,639 | $3,824,000 | 0.62% |
| Sofinnova Investments, Inc. | 333,707 | $10,322,000 | 0.61% |